Compare SBR & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBR | AMPH |
|---|---|---|
| Founded | 1982 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | N/A | 2005 |
| Metric | SBR | AMPH |
|---|---|---|
| Price | $74.02 | $19.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $30.29 |
| AVG Volume (30 Days) | 30.7K | ★ 581.3K |
| Earning Date | 02-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.60% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.03 |
| Revenue | N/A | ★ $719,887,000.00 |
| Revenue This Year | N/A | $7.34 |
| Revenue Next Year | N/A | $4.81 |
| P/E Ratio | $12.77 | ★ $9.36 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $58.25 | $17.03 |
| 52 Week High | $84.39 | $31.26 |
| Indicator | SBR | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 54.96 | 32.55 |
| Support Level | $65.77 | N/A |
| Resistance Level | $79.86 | $28.56 |
| Average True Range (ATR) | 1.83 | 1.09 |
| MACD | 0.12 | -0.09 |
| Stochastic Oscillator | 51.86 | 32.08 |
Sabine Royalty Trust is an express trust which is formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.